Search Within

Department of Medicine

Formats
  1. Journal Article (19620)
  2. Meeting Abstract (16084)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22367)
  2. Hematologic Malignancies, Division of (13308)
  3. Center for Hematologic Malignancies (11082)
  4. GSK Faculty (10658)
  5. Survivorship Research (9352)
  6. Division of Subspecialty Medicine (7560)

More Groups

People
  1. Robert Motzer (1251)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1158)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2304)
  6. Nature Publishing Group (2122)

More Publishers

Results (39711)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Atallah, E. L.; Mauro, M. J.; Sasaki, K.; Levy, M. Y.; Koller, P. B.; Sadek, I.; Yang, D.; Ruckel-Kumar, J.; Khan, M. H.; Cortes, J. E.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Verstovsek, S.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E. M.; Mauro, M. J.; Rampal, R.; Bose, P.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer
    Meeting Abstract

    Abdelhamid Ahmed, A. H.; Russell, M. D.; Kyriazidis, N.; Silver Karcioglu, A.; Sherman, E. J.; Ho, A. L.; Fagin, J. A.; Wong, R. J.; Busaidy, N. L.; Zafereo, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation
    Meeting Abstract

    Ponce, D. M.; Kosuri, S.; Khera, N.; DeFilipp, Z. M.; Lombardo, M. J.; Ford, C. B.; Peled, J. U.; Van Den Brink, M. R. M.; von Moltke, L.; Tejura, B.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study
    Meeting Abstract

    Gao, X.; Smith, M. R.; Scher, H. I.; Verholen, F.; Adorjan, P.; Dissanayake, M.; Laccetti, A. L.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • PSMAddition: A phase 3 trial to compare treatment with (177)Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer
    Meeting Abstract

    Tagawa, S. T.; Sartor, A. O.; Saad, F.; Reid, A. H.; Sakharova, O. V.; Feng, F. Y.; Fizazi, K.; Morris, M. J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A multi-center natural history study of precision-based genomics in prostate cancer (PC)
    Meeting Abstract

    Beltran, H.; Mateo, J.; Abida, W.; McKay, R. R.; Montgomery, R.t B.; Aggarwal, Rahul Raj; Lee-Wisdom, K.; Figg, W. D.; Dahut, W. L.; Karzai, F.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CRI-CCTG-0003/IND.240: An immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC)
    Meeting Abstract

    Mackay, H.; Tinker, A.; Nelson, B.; Zamarin, D.; Odunsi, K.; Lheureux, S.; Ellard, S.; Smrke, A.; Gaudreau, P. O.; Faulkner, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer
    Meeting Abstract

    Moore, K. N.; Bouberhan, S.; Hamilton, E. P.; Liu, J. F.; O'Cearbhaill, R. E.; O'Malley, D. M.; Papadamitriou, K.; Schröder, D.; Van N., Els; Yoo, S. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC)
    Meeting Abstract

    Hays, J. L.; Friedman, C. F.; Lakhani, N.; Anderson, C. K.; Buscema, J.; Duska, L. R.; Hamilton, E. P.; Taylor, S. E.; Carrington, C.; Burger, R. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save